Takeda Pharmaceutical Co. Ltd. has paid $50m upfront to acquire exclusive commercialization rights in Japan to Exelixis Inc.'s oral small molecule cancer drug cabozantinib, for all potential indications including advanced renal cell carcinoma (RCC).
Takeda Adds Exelixis Arrow To Oncology Quiver
Takeda's acquisition of Japanese rights to Exelixis' lead product fills a gap in the oncology portfolio while adding another piece to the US company's global licensing jigsaw.
